[Anti-angiogenesis effect of G4PAMAM/VEGFASODN on breast cancer in vitro].
To investigate the effect of G4PAMAM/VEGFASODN compound on expression of VEGF and VEGF mRNA in MDA-MB-231 breast cancer cells and the growth inhibition of vascular endothelial cells.



The diameter of G4PAMAM/VEGFASODN granule was measured by transmission electron microscopy, and its stability under different pH was also observed. The efficiency of transfection in vitro was detected by flow cytometer and the positively transfected cells were detected by laser scanning confocal microscope. The survival rate and the inhibitory rate of vascular endothelial cells were determined by MTT assay. The expression of protein VEGF was detected by immunohistochemical method and the expression of VEGF mRNA was detected by RT-PCR.



The diameter of G4PAMAM/VEGFASODN granules was about 10 nm and it arranged as homogeneous netlike. Under pH 5-10 G4PAMAM/VEGFASODN presented highly stable and no dissociation was observed with different charge ratios. The 48-hour transfection rate of G4PAMAM/VEGFASODN in charge ratio of 1:40 was significantly higher than that of the lipofectamine group. None of the transfection products in each group showed cell toxicity. The staining of VEGF protein in the cytoplasm of MDA-MB-231 cells after G4PAMAM/ASODN transfection weakened markedly, and the positive expression rate decreased. Meanwhile, the VEGF mRNA expression was also decreased.



With good stability and transfection rate, compound G4PAMAM/VEGFASODN can be a promising new nanometer vector of gene transfer system. The G4PAMAM/VEGFASODN can inhibit the expression of VEGF gene specifically and efficiently, which may be used for in vivo animal experiment.
Zhao
Xin-han
XH
Department of Medical Ontology, The First Affiliated Hospital, Medical School, Xi'an Jiaotong University, Xi'an 710061, China. zhaoxinhan@mail.xjtu.edu.cn
Li
Li
L
Wang
Zhi-yu
ZY
Znang
Ling-xiao
LX
An
Gai-li
GL
D020533:Angiogenesis Inhibitors / Q000235:genetics / Q000494:pharmacology*; D001943:Breast Neoplasms / Q000098:blood supply* / Q000235:genetics / Q000473:pathology; D045744:Cell Line, Tumor; D050091:Dendrimers / Q000494:pharmacology*; D006801:Humans; D053758:Nanoparticles; D009757:Nylons / Q000494:pharmacology*; D016376:Oligonucleotides, Antisense / Q000494:pharmacology*; D012333:RNA, Messenger / Q000378:metabolism; D014162:Transfection; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics / Q000378:metabolism*
D020533:Angiogenesis Inhibitors; D050091:Dendrimers; D009757:Nylons; D016376:Oligonucleotides, Antisense; C520550:PAMAM-G4; D012333:RNA, Messenger; D042461:Vascular Endothelial Growth Factor A